165 related articles for article (PubMed ID: 32410793)
1. Efficacy of platinum in advanced triple-negative breast cancer with germline
Wang N; Li K; Huang W; Kong W; Liu X; Shi W; Xie F; Jiang H; Song G; Di L; Wang Q; Yu J; Li H
Chin J Cancer Res; 2020 Apr; 32(2):149-162. PubMed ID: 32410793
[TBL] [Abstract][Full Text] [Related]
2. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
Pavese F; Capoluongo ED; Muratore M; Minucci A; Santonocito C; Fuso P; Concolino P; Di Stasio E; Carbognin L; Tiberi G; Garganese G; Corrado G; Di Leone A; Generali D; Fragomeni SM; D'Angelo T; Franceschini G; Masetti R; Fabi A; Mulè A; Santoro A; Belli P; Tortora G; Scambia G; Paris I
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230495
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study.
Chen X; Qian X; Xiao M; Zhang P
Breast Cancer (Dove Med Press); 2023; 15():671-682. PubMed ID: 37692097
[TBL] [Abstract][Full Text] [Related]
4. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
5. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
[TBL] [Abstract][Full Text] [Related]
6. Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis.
Jiang Y; Meng XY; Deng NN; Meng C; Li LH; He ZK; Wang XY; Song ZY; Cui RJ
Front Oncol; 2021; 11():718761. PubMed ID: 34490117
[TBL] [Abstract][Full Text] [Related]
7. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
8. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Chen Y; Zhang J; Hu XC; Wang BY; Wang ZH; Wang LP; Cao J; Tao ZH; Du YQ; Zhao YN; Gong CC; Jin J
Ann Palliat Med; 2020 Sep; 9(5):3018-3027. PubMed ID: 32787354
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
10. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling Comparison of Germline
Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
Front Oncol; 2020; 10():583314. PubMed ID: 33194720
[No Abstract] [Full Text] [Related]
12. Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.
Lee IH; Lee SJ; Kim J; Lee YH; Chong GO; Kim JM; Lee J; Lee NY; Park SY; Hong DG; Chae YS
Cancer Chemother Pharmacol; 2024 Apr; ():. PubMed ID: 38652271
[TBL] [Abstract][Full Text] [Related]
13. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience.
Hong R; Ma F; Xu B; Li Q; Zhang P; Yuan P; Wang J; Fan Y; Cai R
Anticancer Drugs; 2014 Oct; 25(9):1089-94. PubMed ID: 25153786
[TBL] [Abstract][Full Text] [Related]
17. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
Wang X; Yue J; Kang YK; Gao SL; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
[No Abstract] [Full Text] [Related]
18. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy.
Zhang J; Fan M; Xie J; Wang Z; Wang B; Zhang S; Wang L; Cao J; Tao Z; Li T; Hu X
Oncotarget; 2015 Dec; 6(40):43135-43. PubMed ID: 26447756
[TBL] [Abstract][Full Text] [Related]
20. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
